{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:08:45Z","timestamp":1794956925690,"version":"4.9.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Royal Free Charity"},{"DOI":"10.13039\/501100008604","name":"Scleroderma & Raynaud\u2019s","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008604","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Cytokines released by infiltrating T cells may promote mechanisms leading to fibrosis in scleroderma. The aim of this study was to investigate the role of the Th2 cytokine IL-31, and its receptor IL-31RA, in scleroderma skin and lung fibrosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>IL-31 was measured by ELISA of plasma, and by immunochemistry of fibrotic skin and lung tissue of scleroderma patients. The receptor, IL-31RA, was assayed by qPCR of tissue resident cells. Next-generation sequencing was used to profile the responses of normal skin fibroblasts to IL-31. In wild-type Balb\/c mice, IL-31 was administered by subcutaneous mini pump, with or without additional TGF\u03b2, and the fibrotic reaction measured by histology and ELISA of plasma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>IL-31 was present at high levels in plasma and fibrotic skin and lung lesions in a subset of scleroderma patients, and the receptor overexpressed by downstream cells relevant to the disease process, including skin and lung fibroblasts, through loss of epigenetic regulation by miR326. In skin fibroblasts, IL-31 induced next generation sequencing profiles associated with cellular growth and proliferation, anaerobic metabolism and mineralization, and negatively associated with angiogenesis and vascular repair, as well as promoting phenotype changes including migration and collagen protein release via pSTAT3, resembling the activation state in the disease. In mice, IL-31 induced skin and lung fibrosis. No synergy was seen with TGF\u03b2, which supressed IL-31RA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>IL-31\/IL-31RA is confirmed as a candidate pro-fibrotic pathway, which may contribute to skin and lung fibrosis in a subset of scleroderma patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa195","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T11:12:10Z","timestamp":1585653130000},"page":"2625-2636","source":"Crossref","is-referenced-by-count":51,"title":["Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma"],"prefix":"10.1093","volume":"59","author":[{"given":"Bodoor","family":"Yaseen","sequence":"first","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Lopez","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"},{"name":"MuriGenics, Inc, Vallejo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Taki","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Zafar","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Rosario","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahja Ahmed","family":"Abdi","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivanee","family":"Vigneswaran","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Xing","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Arumalla","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Black","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimti","family":"Kumar","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Gul","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Scolamiero","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian","family":"Morris","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bowman","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Imperial College London, Royal Brompton Campus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Stainer","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Imperial College London, Royal Brompton Campus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Rice","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Imperial College London, Royal Brompton Campus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Stock","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Imperial College London, Royal Brompton Campus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Renzoni","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Imperial College London, Royal Brompton Campus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Venturini","sequence":"additional","affiliation":[{"name":"Pathogen Genomics Unit, UCL, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Health and Life Sciences, Northumbria University, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Department of Health and Life Sciences, Northumbria University, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stratton","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"2020082700371729700_keaa195-B1","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2020082700371729700_keaa195-B2","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2020082700371729700_keaa195-B3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ajhg.2013.12.002","article-title":"Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis","volume":"94","author":"Mayes","year":"2014","journal-title":"Am J Hum Genet"},{"key":"2020082700371729700_keaa195-B4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00281-015-0499-z","article-title":"Genetics of systemic sclerosis","volume":"37","author":"Bossini-Castillo","year":"2015","journal-title":"Semin Immunopathol"},{"key":"2020082700371729700_keaa195-B5","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1136\/annrheumdis-2015-208154","article-title":"Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway","volume":"75","author":"Lopez-Isac","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020082700371729700_keaa195-B6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/art.1780200410","article-title":"Cellular infiltrates in scleroderma skin","volume":"20","author":"Fleischmajer","year":"1977","journal-title":"Arthritis Rheum"},{"key":"2020082700371729700_keaa195-B7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/path.1711660307","article-title":"Sequential dermal microvascular and perivascular changes in the development of scleroderma","volume":"166","author":"Prescott","year":"1992","journal-title":"J Pathol"},{"key":"2020082700371729700_keaa195-B8","first-page":"1751","article-title":"Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis","volume":"151","author":"Mavalia","year":"1997","journal-title":"Am J Pathol"},{"key":"2020082700371729700_keaa195-B9","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI116015","article-title":"Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4","volume":"90","author":"Postlethwaite","year":"1992","journal-title":"J Clin Invest"},{"key":"2020082700371729700_keaa195-B10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/art.37706","article-title":"Interleukin-13\u2013producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis","volume":"65","author":"Fuschiotti","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2020082700371729700_keaa195-B11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2020082700371729700_keaa195-B12","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2020082700371729700_keaa195-B13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"2020082700371729700_keaa195-B14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"key":"2020082700371729700_keaa195-B15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cytogfr.2008.08.003","article-title":"Structures and biological functions of IL-31 and IL-31 receptors","volume":"19","author":"Zhang","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"2020082700371729700_keaa195-B16","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2340\/00015555-2417","article-title":"Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin","volume":"96","author":"Nattkemper","year":"2016","journal-title":"Acta Dermato Venereol"},{"key":"2020082700371729700_keaa195-B17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.5021\/ad.2011.23.4.468","article-title":"IL-31 serum protein and tissue mRNA levels in patients with atopic dermatitis","volume":"23","author":"Kim","year":"2011","journal-title":"Ann Dermatol"},{"key":"2020082700371729700_keaa195-B18","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMc1704013","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Egeberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2020082700371729700_keaa195-B19","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1365-2567.2007.02668.x","article-title":"Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response","volume":"122","author":"Ip","year":"2007","journal-title":"Immunology"},{"key":"2020082700371729700_keaa195-B20","doi-asserted-by":"crossref","first-page":"e29815","DOI":"10.1371\/journal.pone.0029815","article-title":"Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"2020082700371729700_keaa195-B21","doi-asserted-by":"crossref","first-page":"e0161877","DOI":"10.1371\/journal.pone.0161877","article-title":"IL-31-driven skin remodeling involves epidermal cell proliferation and thickening that lead to impaired skin-barrier function","volume":"11","author":"Singh","year":"2016","journal-title":"PLoS One"},{"key":"2020082700371729700_keaa195-B22","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/bjd.14998","article-title":"Itch and systemic sclerosis: frequency, clinical characteristics and consequences","volume":"176","author":"Th\u00e9r\u00e9n\u00e9","year":"2017","journal-title":"Br J Dermatol"},{"key":"2020082700371729700_keaa195-B23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jpainsymman.2015.12.314","article-title":"The impact of pain and itch on functioning and health-related quality of life in systemic sclerosis: an exploratory study","volume":"52","author":"Racine","year":"2016","journal-title":"J Pain Symptom Manag"},{"key":"2020082700371729700_keaa195-B24","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2020082700371729700_keaa195-B25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI12020","article-title":"Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients","volume":"108","author":"Stratton","year":"2001","journal-title":"J Clin Invest"},{"key":"2020082700371729700_keaa195-B26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nature Biotechnology"},{"key":"2020082700371729700_keaa195-B27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1755-1536-6-10","article-title":"Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts","volume":"6","author":"Donovan","year":"2013","journal-title":"Fibrogenesis Tissue Repair"},{"key":"2020082700371729700_keaa195-B28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2144\/000112729","article-title":"Standardized quantification of pulmonary fibrosis in histological samples","volume":"44","author":"H\u00fcbner","year":"2008","journal-title":"Biotechniques"},{"key":"2020082700371729700_keaa195-B29","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/jid.2013.227","article-title":"IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus","volume":"133","author":"Singer","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2020082700371729700_keaa195-B30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00296-016-3422-6","article-title":"The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus","volume":"36","author":"Huang","year":"2016","journal-title":"Rheumatol Int"},{"key":"2020082700371729700_keaa195-B31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: the role of increased skin interleukin-31","volume":"179","author":"Kim","year":"2018","journal-title":"Br J Dermatol"},{"key":"2020082700371729700_keaa195-B32","doi-asserted-by":"crossref","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PLoS One"},{"key":"2020082700371729700_keaa195-B33","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","article-title":"Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat Commun"},{"key":"2020082700371729700_keaa195-B34","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/9\/2625\/33686376\/keaa195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/9\/2625\/33686376\/keaa195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T04:37:45Z","timestamp":1598503065000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/9\/2625\/5829672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,5,4]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa195","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,5,4]]}}}